Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Online adaptive IMRT with concurrent gemcitabine for pancreatic cancer
jRCT1051230087Active, not recruiting
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC) (2 arms). Primary endpoint: Acute Grade 3 or higher gastrointestinal adverse event non-incident rate. Started Nov 2023; status: active, not recruiting.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCT1051230087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051230087.